Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen

Journal of Clinical Oncology

Volumn 23, Issue 21, 2005, Pages 4687-4694

  Arpino, G ^a   Weiss, H L ^a   Clark, G M ^a   Hilsenbeck, S G ^a   Osborne, C Kent ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CONTROLLED STUDY; FOLLOW UP; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PLOIDY; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CHEMISTRY; FEMALE; SECOND CANCER; STATISTICAL MODEL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LOGISTIC MODELS; NEOPLASMS, SECOND PRIMARY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 23044461420     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.076     Document Type: Article

References (34)

1. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351: 1451-1467, 1998
2. Fisher B, Anderson S, Tan-Chiu E, et al: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19:931-942, 2001
3. Hutchins L, Green S, Ravdin P, et al: CMF versus CAF +/- tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: Update of tamoxifen results. Breast Cancer Res Treat 57:25, 1999 (abstr 1)
4. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
5. McGuire WL, De La Garza M, Chamness GC: Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res 37:637-639, 1977
6. Powell B, Garola RE, Chamness GC, et al: Measurement of progesterone receptor in human breast cancer biopsies. Cancer Res 39: 1678-1682, 1979
7. Dressler LG, Seamer LC, Owens MA, et al: DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61:420-427, 1988
8. Clark GM, Dressler LG, Owens MA, et al: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320:627-633, 1989
9. Clark GM, Wenger CR, Beardslee S, et al: How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer 71:2157-2162, 1993
10. Cuzick J: Aromatase inhibitors in prevention: Data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 163:96-103; discussion 264-266, 2003
11. Hutchings O, Evans G, Fallowfield L, et al: Effect of early American results on patients in a tamoxifen prevention trial (IBIS): International Breast Cancer Intervention Study. Lancet 352: 1222, 1998
12. Hull DF III, Clark GM, Osborne CK, et al: Multiple estrogen receptor assays in human breast cancer. Cancer Res 43:413-416, 1983
13. Tarone RE, Chu KC: The greater impact of menopause on ER- than ER+ breast cancer incidence: A possible explanation (United States). Cancer Causes Control 13:7-14, 2002
14. Clark GM, Osborne CK, McGuire WL: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2:1102-1109, 1984
15. Rutqvist LE, Johansson H, Signomklao T, et al: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies: Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87:645-651, 1995
16. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989
17. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542, 1996
18. Coradini D, Oriana S, Manani L, et al: Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? Eur J Cancer 34:825-830, 1998
19. Swain SM, Wilson J. Eleftherios J, et al: Estrogen receptor (ER) status of primary breast cancer is predictive of ER status of contralateral breast cancer (CBC). J Natl Cancer Inst 96:516-523, 2004
20. Fisher B, Anderson S, DeCillis A, et al: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17:3374-3388, 1999
21. Fisher B, Anderson S, Wickerham DL, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15: 1858-1869, 1997
22. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997
23. Robson M, Gilewski T, Haas B, et al: BRCA-associated breast cancer in young women. J Clin Oncol 16:1642-1649, 1998
24. Lancaster JM, Carney ME, Futreal PA: BRCA 1 and 2: A genetic link to familial breast and ovarian cancer. Medscape Womens Health 2:7, 1997
25. Rutqvist LE, Cedermark B, Glas U, et al: Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 83:1299-1306, 1991
26. Kaas R, Peterse JL, Hart AA, et al: The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer. Br J Cancer 88:707-710, 2003
27. Li CI, Malone KE, Weiss NS, et al: Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 93:1008-1013, 2001
28. Bachleitner-Hofmann T, Pichler-Gebhard B, Rudas M, et al: Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen. Clin Cancer Res 8:3427-3432, 2002
29. Osborne CK, Bardou V, Hopp TA, et al: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361, 2003
30. Shou J, Massarweh S, Osborne CK, et al: Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926-935, 2004
31. Chang J, Clark GM, Allred DC, et al: Survival of patients with metastatic breast carcinoma: Importance of prognostic markers of the primary tumor. Cancer 97:545-553, 2003
32. Wenger CR, Beardslee S, Owens MA, et al: DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 28:9-20, 1993
33. Wenger CR, Clark GM: S-phase fraction and breast cancer: A decade of experience. Breast Cancer Res Treat 51:255-265, 1998
34. Hedley DW, Clark GM, Cornelisse CJ, et al: Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast: Report of the DNA Cytometry Consensus Conference. Cytometry 14:482-485, 1993